Workflow
九强生物(300406) - 2025 Q1 - 季度财报
300406BSBE(300406)2025-04-25 07:50

Financial Performance - The company's revenue for Q1 2025 was ¥319,809,793.71, a decrease of 18.81% compared to ¥393,894,885.38 in the same period last year[5] - Net profit attributable to shareholders was ¥83,257,495.41, down 30.99% from ¥120,648,449.77 year-on-year[5] - Basic and diluted earnings per share decreased by 33.33% to ¥0.14 from ¥0.21 in the same period last year[5] - Operating profit for the current period was CNY 98,056,421.38, a decline of 31.9% from CNY 144,380,239.45 in the previous period[19] - The company reported a net profit of CNY 98,024,052.97 for the current period, down from CNY 142,407,950.93 in the previous period, reflecting a decrease of 30.9%[19] - Net profit for the current period is 83,572,615.29, a decrease of 30.6% compared to 120,219,484.04 in the previous period[20] - Total comprehensive income for the current period is 83,536,791.02, down 30.6% from 120,257,352.53 in the previous period[20] Cash Flow - The net cash flow from operating activities increased significantly by 304.24%, reaching ¥70,946,714.51 compared to ¥17,550,800.52 in the previous year[5] - Operating cash flow net amount increased significantly to 70,946,714.51 from 17,550,800.52, representing a growth of 303.5%[22] - Cash inflow from operating activities totaled 366,407,557.92, down 11.3% from 413,326,787.63 in the previous period[22] - Cash outflow from investing activities increased significantly to 137,138,675.41 from 39,384,851.07, indicating a rise of 248.5%[22] - Net cash flow from financing activities was negative at -3,247,940.80, compared to a positive 16,808,061.67 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,631,457,588.22, reflecting a 1.01% increase from ¥5,574,965,162.35 at the end of the previous year[5] - Total assets as of March 31, 2025, amounted to CNY 5,631,457,588.22, up from CNY 5,574,965,162.35 at the beginning of the period[18] - Total liabilities decreased to CNY 1,416,847,031.71 from CNY 1,442,165,213.96, indicating a reduction of 1.8%[18] - The company's short-term borrowings decreased by 63.18% to ¥38,982.51, primarily due to repayment of short-term loans[7] Operating Costs and Inventory - The company's operating costs decreased by 32.77% to ¥61,274,484.14 from ¥91,143,372.70 year-on-year, attributed to a decline in sales[7] - Total operating costs decreased to CNY 222,735,370.83, down 11.7% from CNY 252,157,863.84 in the previous period[19] - Inventory increased to CNY 231,884,150.32 from CNY 220,680,889.10, representing a rise of 5.4%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,231[9] - The company had 11,210,221 convertible bonds remaining with a total face value of CNY 1,121,022,100 as of the end of the first quarter of 2025[13] Investment Performance - The investment loss was reported at ¥-152,998.11, a significant decrease of 113.72% compared to a profit of ¥1,115,166.92 in the previous year[7] - Other comprehensive income attributable to the parent company showed a significant decline, with a net amount of -27,990.36 compared to 27,198.35 in the previous period[20]